Literature DB >> 18309114

Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis.

D L Tharp1, B R Wamhoff, H Wulff, G Raman, A Cheong, D K Bowles.   

Abstract

OBJECTIVE: We previously demonstrated that upregulation of intermediate-conductance Ca(2+)-activated K(+) channels (K(Ca)3.1) is necessary for mitogen-induced phenotypic modulation in isolated porcine coronary smooth muscle cells (SMCs). The objective of the present study was to determine the role of K(Ca)3.1 in the regulation of coronary SMC phenotypic modulation in vivo using a swine model of postangioplasty restenosis. METHODS AND
RESULTS: Balloon angioplasty was performed on coronary arteries of swine using either noncoated or balloons coated with the specific K(Ca)3.1 blocker TRAM-34. Expression of K(Ca)3.1, c-jun, c-fos, repressor element-1 silencing transcription factor (REST), smooth muscle myosin heavy chain (SMMHC), and myocardin was measured using qRT-PCR in isolated medial cells 2 hours and 2 days postangioplasty. K(Ca)3.1, c-jun, and c-fos mRNA levels were increased 2 hours postangioplasty, whereas REST expression decreased. SMMHC expression was unchanged at 2 hours, but decreased 2 days postangioplasty. Use of TRAM-34 coated balloons prevented K(Ca)3.1 upregulation and REST downregulation at 2 hours, SMMHC and myocardin downregulation at 2 days, and attenuated subsequent restenosis 14 and 28 days postangioplasty. Immunohistochemical analysis demonstrated corresponding changes at the protein level.
CONCLUSIONS: Blockade of K(Ca)3.1 by delivery of TRAM-34 via balloon catheter prevented smooth muscle phenotypic modulation and limited subsequent restenosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18309114      PMCID: PMC2652246          DOI: 10.1161/ATVBAHA.107.155796

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  39 in total

1.  Molecular cloning and characterization of the intermediate-conductance Ca(2+)-activated K(+) channel in vascular smooth muscle: relationship between K(Ca) channel diversity and smooth muscle cell function.

Authors:  C B Neylon; R J Lang; Y Fu; A Bobik; P H Reinhart
Journal:  Circ Res       Date:  1999-10-29       Impact factor: 17.367

2.  Molecular mechanisms of decreased smooth muscle differentiation marker expression after vascular injury.

Authors:  C P Regan; P J Adam; C S Madsen; G K Owens
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

3.  Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences.

Authors:  S Ghanshani; H Wulff; M J Miller; H Rohm; A Neben; G A Gutman; M D Cahalan; K G Chandy
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

Review 4.  The experimental animal models for assessing treatment of restenosis.

Authors:  B Kantor; K Ashai; D R Holmes; R S Schwartz
Journal:  Cardiovasc Radiat Med       Date:  1999 Jan-Mar

5.  Prevention of restenosis: is angioplasty the answer?

Authors:  Bruno Scheller; Ulrich Speck; Michael Böhm
Journal:  Heart       Date:  2007-05       Impact factor: 5.994

Review 6.  Chromatin crosstalk in development and disease: lessons from REST.

Authors:  Lezanne Ooi; Ian C Wood
Journal:  Nat Rev Genet       Date:  2007-07       Impact factor: 53.242

7.  Phenotypic modulation of vascular smooth muscle cells: dissection of transcriptional regulatory mechanisms.

Authors:  R Nagai; T Suzuki; K Aizawa; S Miyamoto; T Amaki; K Kawai-Kowase; K I Sekiguchi; M Kurabayashi
Journal:  Ann N Y Acad Sci       Date:  2001-12       Impact factor: 5.691

8.  Delineation of the clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-activated potassium channel, IKCa1.

Authors:  H Wulff; G A Gutman; M D Cahalan; K G Chandy
Journal:  J Biol Chem       Date:  2001-06-25       Impact factor: 5.157

Review 9.  Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications.

Authors:  Heike Wulff; Aaron Kolski-Andreaco; Ananthakrishnan Sankaranarayanan; Jean-Marc Sabatier; Vikram Shakkottai
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

10.  Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant.

Authors:  H Wulff; M J Miller; W Hansel; S Grissmer; M D Cahalan; K G Chandy
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

View more
  50 in total

1.  Store-operated Ca(2+) entry is not essential for PDGF-BB induced phenotype modulation in rat aortic smooth muscle.

Authors:  Craig A Emter; Douglas K Bowles
Journal:  Cell Calcium       Date:  2010-07       Impact factor: 6.817

2.  KCa 3.1 channels maintain endothelium-dependent vasodilatation in isolated perfused kidneys of spontaneously hypertensive rats after chronic inhibition of NOS.

Authors:  Serge Simonet; Marc Isabelle; Mélanie Bousquenaud; Nicolas Clavreul; Michel Félétou; Christine Vayssettes-Courchay; Tony J Verbeuren
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

3.  Calcium-activated potassium channel KCa3.1 in lung dendritic cell migration.

Authors:  Zhifei Shao; Toluwalope O Makinde; Devendra K Agrawal
Journal:  Am J Respir Cell Mol Biol       Date:  2011-04-14       Impact factor: 6.914

Review 4.  Calcium-activated potassium channels and endothelial dysfunction: therapeutic options?

Authors:  Michel Félétou
Journal:  Br J Pharmacol       Date:  2009-01-29       Impact factor: 8.739

Review 5.  Endothelial Ca+-activated K+ channels in normal and impaired EDHF-dilator responses--relevance to cardiovascular pathologies and drug discovery.

Authors:  Ivica Grgic; Brajesh P Kaistha; Joachim Hoyer; Ralf Köhler
Journal:  Br J Pharmacol       Date:  2009-03-19       Impact factor: 8.739

6.  Focused in vivo delivery of plasmid DNA to the porcine vascular wall via intravascular ultrasound destruction of microbubbles.

Authors:  Linsey C Phillips; Alexander L Klibanov; Douglas K Bowles; Michael Ragosta; John A Hossack; Brian R Wamhoff
Journal:  J Vasc Res       Date:  2009-11-18       Impact factor: 1.934

7.  The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease.

Authors:  Xiaoqin Hua; Tobias Deuse; Yi-Je Chen; Heike Wulff; Mandy Stubbendorff; Ralf Köhler; Hiroto Miura; Florian Länger; Hermann Reichenspurner; Robert C Robbins; Sonja Schrepfer
Journal:  Transplantation       Date:  2013-01-27       Impact factor: 4.939

8.  Topical Delivery of Senicapoc Nanoliposomal Formulation for Ocular Surface Treatments.

Authors:  Jie Liang Phua; Aihua Hou; Yuan Siang Lui; Tanima Bose; George Kanianthara Chandy; Louis Tong; Subbu Venkatraman; Yingying Huang
Journal:  Int J Mol Sci       Date:  2018-09-29       Impact factor: 5.923

Review 9.  Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease.

Authors:  Ralf Köhler; Brajesh P Kaistha; Heike Wulff
Journal:  Expert Opin Ther Targets       Date:  2010-02       Impact factor: 6.902

10.  Severe familial hypercholesterolemia impairs the regulation of coronary blood flow and oxygen supply during exercise.

Authors:  Shawn B Bender; Vincent J de Beer; Darla L Tharp; Douglas K Bowles; M Harold Laughlin; Daphne Merkus; Dirk J Duncker
Journal:  Basic Res Cardiol       Date:  2016-09-13       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.